# Douglas A. Levine

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/douglas-a-levine/

## Facts

| Field | Value |
| --- | --- |
| Citations | 124,621 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 130 |
| i10-index | 320 |
| Last Known Institution | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| OpenAlex ID | https://openalex.org/A5036444245 |
| ORCID iD | https://orcid.org/0000-0003-1038-8232 |
| Works | 828 |

## Researcher papers

- [Integrated genomic analyses of ovarian carcinoma](https://scholariq.org/papers/integrated-genomic-analyses-of-ovarian-carcinoma/)
- [OncoKB: A Precision Oncology Knowledge Base](https://scholariq.org/papers/oncokb-a-precision-oncology-knowledge-base/)
- [Rethinking ovarian cancer: recommendations for improving outcomes](https://scholariq.org/papers/rethinking-ovarian-cancer-recommendations-for-improving-outcomes/)
- [Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer](https://scholariq.org/papers/integrated-proteogenomic-characterization-of-human-high-grade-serous-ovarian/)
- [Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk](https://scholariq.org/papers/common-genetic-variation-in-cellular-transport-genes-and-epithelial-ovarian/)
- [Network modeling links breast cancer susceptibility and centrosome dysfunction](https://scholariq.org/papers/network-modeling-links-breast-cancer-susceptibility-and-centrosome-dysfunction/)
- [Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm](https://scholariq.org/papers/improved-progression-free-and-overall-survival-in-advanced-ovarian-cancer-as-a/)
- [A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24](https://scholariq.org/papers/a-genome-wide-association-study-identifies-susceptibility-loci-for-ovarian/)
- [Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer](https://scholariq.org/papers/genomic-and-biological-characterization-of-exon-4-kras-mutations-in-human-cancer/)
- [Sentinel lymph node mapping for grade 1 endometrial cancer: Is it the answer to the surgical staging dilemma?](https://scholariq.org/papers/sentinel-lymph-node-mapping-for-grade-1-endometrial-cancer-is-it-the-answer-to/)
- [Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types](https://scholariq.org/papers/genome-wide-meta-analyses-of-breast-ovarian-and-prostate-cancer-association/)
- [Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study](https://scholariq.org/papers/association-of-vitamin-d-levels-and-risk-of-ovarian-cancer-a-mendelian/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Researcher university

- [Merck & Co., Inc., Rahway, NJ, USA (United States)](https://scholariq.org/institutions/merck-and-co-inc-rahway-nj-usa-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.